Core Insights - Cytokinetics has appointed James M. Daly to its Board of Directors, effective August 19, 2025, bringing over 30 years of biopharmaceutical leadership experience [1][2] - Mr. Daly's expertise includes leading commercial launches of innovative therapies and guiding global biopharma companies [2] - Cytokinetics is advancing its pipeline of potential new medicines for cardiac muscle dysfunction, including aficamten and omecamtiv mecarbil [3] Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology [3] - The company is preparing for potential regulatory approvals and commercialization of aficamten, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [3] - Other products in development include omecamtiv mecarbil for heart failure with severely reduced ejection fraction, ulacamten for heart failure with preserved ejection fraction, and CK-089 for muscular dystrophy [3]